Center for Excellence in Drug Safety and Pharmacovigilance

Merck’s Potential Blockcuster Tredaptive Fails Phase III Hurdle – Leads to EMA Analysis

Merck’s Phase III program for Tredaptive comes to an end secondary to both safety and efficiacy concerns. For more information click here.

Leave a Reply

Your email address will not be published. Required fields are marked *